US 12,467,066 B2Granted

Compositions and methods for treating retinal disorders

AssigneeUCL Business PLC

InventorsRobin Ali, Takaaki Matsuki, Alexander Smith, Anastasios Georgiadis

Life of this patent

Estimating the term…

Abstract

The present invention relates to the prevention and/or treatment of retinal disorders, such as cone dystrophies, cone-rod dystrophies, in particular Achromatopsia.

Claims29

Dependent claims

A transcriptional control unit (TCU) of up to 2500 nucleotides in length comprising in a 5′ to 3′ direction:

(a) a Locus Control Region (LCR) comprising SEQ ID NO:
1, and
(b) a promoter element comprising SEQ ID NO:
3.

1 more element

Dependencies are inferred from the claim text.

Facts

Application: 18/336,409Filed 16 Jun 2023 · continuation
Priority: GB 180054612 Jan 2018
Published: US 2024/0067989 A129 Feb 2024
Granted: 11 Nov 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification14 codes

C12N 15/85
Vectors or expression systems specially adapted for eukaryotic hosts: for animal cells
C12N 15/861
Viral vectors: adenoviral vectors
A61K 35/761
Viruses; Subviral particles; Bacteriophages: adenovirus
A61K 39/235
Viral antigens: adenoviridae

Family

PCT/GB2019/050092Parent of this continuation · filed 14 Jan 2019
US 2024/0067989 A1Pre-grant publication · published 29 Feb 2024
Application16/961,857Parent of this continuation
US 11,680,276 B2Parent of this continuation
US 2020/0392536 A1Published application
US 12,467,066 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results